Special Issue "Tumour Associated Dendritic Cells"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (28 February 2019)
The key role of dendritic cells (DC) in priming adaptive immune responses has long been harnessed for cancer vaccines. Although there is clear evidence that DC vaccines are well tolerated and can induce tumour immune responses, overall they have been of limited clinical benefit. Despite their long history in the clinic, the role of DC in tumour tissue is not well understood and has been confounded by their rarity, heterogeneity and overlapping markers with other myeloid populations. DC can be divided into distinct subsets with highly specialized functions. In a number of mouse tumour models the cDC1 DC subset has been shown to be required for priming anti-tumour immunity and for the efficacy of immunotherapies. These findings reinvigorate manipulation of DC as an attractive strategy to induce or improve immune responses in cancer patients. In this Special Issue, we welcome submissions that will help to build a more complete picture of the role of DC in cancer and particularly welcome submissions on the role of DC subsets in a variety of cancer types, human cancers and new ways in which they may be harnessed to improve tumour immune responses.
A/Prof. Dr. Kristen Radford
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.